drugset / Trial / NCT05372354
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Timeline
- Start
- 2022-10-18
- Primary completion
- 2026-10-12
- Completion
- 2026-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EZOBRESIB | Small molecule | — | — |
| Subject | Mezigdomide | Small molecule | — | — |
| Subject | Tazemetostat | Small molecule | — | — |
| Subject | Trametinib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |